HER2-Negative Breast Cancer Terminated Phase 2 Trials for Everolimus (DB01590)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0072181 (HER2-Negative Breast Cancer) | Terminated | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Treatment |